Cargando…

Establishment and Characterization of Acquired Resistance to Platinum Anticancer Drugs in Human Ovarian Carcinoma Cells

To investigate differences in resistance to cis‐diamminedichloroplatinum(II) (CDDP) and diammine (1,1‐cyclobutanecarboxylato)platinum(II) (CBDCA), and their newly developed derivative, ((—)‐(R)‐2‐aminomethylpyrrolidine (1,1‐cyclobutanedicarboxylato)platinum (II)) (DWA2114R), four types of resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Misawa, Toshiya, Kikkawa, Fumitaka, Maeda, Osamu, Obata, Naoko H., Higashide, Koji, Suganuma, Nobuhiko, Tomoda, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1995
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920572/ https://www.ncbi.nlm.nih.gov/pubmed/7737915 http://dx.doi.org/10.1111/j.1349-7006.1995.tb02992.x

Ejemplares similares

Potentiation of cis‐Diammine(1, 1‐cyclobutanedicarboxylato)platinum(II) by Amphotericin B in BALB/c Nude Mice Bearing Human Ovarian Carcinoma Cells
por: Kojima, Masayoshi, et al.
Publicado: (1994)

Is cell block technique useful to predict histological type in patients with ovarian mass and/or body cavity fluids?
por: Maseki, Zenta, et al.
Publicado: (2020)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Ovarian cancer‐associated mesothelial cells induce acquired platinum‐resistance in peritoneal metastasis via the FN1/Akt signaling pathway
por: Yoshihara, Masato, et al.
Publicado: (2020)

Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms.
por: Tamakoshi, K., et al.
Publicado: (1997)

Comparison of prognoses according to non‐positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
por: Maeda, Osamu, et al.
Publicado: (2016)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Anticancer Platinum Drugs Update
por: Ciarimboli, Giuliano
Publicado: (2021)

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
por: Diaz Osterman, Carlos J, et al.
Publicado: (2019)

Chiral discrimination in platinum anticancer drugs.
por: Benedetti, Michele, et al.
Publicado: (2002)

Monofunctional Platinum(II) Anticancer Agents
por: Jin, Suxing, et al.
Publicado: (2021)

Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients
por: Hattori, Satomi, et al.
Publicado: (2016)

Sequence‐dependent Termination of Mammalian DNA Polymerase Reaction by a New Platinum Compound, (–)‐(R)‐2‐Aminomethylpyrrolidine(1,1‐cyclobutane‐dicarboxylato)‐2‐platinum(II) Monohydrate
por: Iwata, Mitsumasa, et al.
Publicado: (1991)

Platinum Derivatives Effects on Anticancer Immune Response
por: Rébé, Cédric, et al.
Publicado: (2019)

Ovarian torsion due to ovarian hyperstimulation syndrome diagnosed by sonographic whirlpool sign in the first trimester of pregnancy: A case report
por: Higashide, Ryo, et al.
Publicado: (2023)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Estrogen producing ovarian fibrosarcoma: A case report
por: Miura, Mayo, et al.
Publicado: (2019)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
por: Olszewski, Ulrike, et al.
Publicado: (2010)

Novel Silver-Platinum Nanoparticles for Anticancer and Antimicrobial Applications
por: López Ruiz, Aida, et al.
Publicado: (2020)

Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes
por: Bolitho, Elizabeth M., et al.
Publicado: (2021)

Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
por: Jeon, Jaewan, et al.
Publicado: (2021)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Copy number footprints of platinum-based anticancer therapies
por: Gonzalez, Santiago, et al.
Publicado: (2023)

The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma
por: Lu, Enzhou, et al.
Publicado: (2022)

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance
por: Deng, Zhiqin, et al.
Publicado: (2023)

Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~
por: Kajiyama, Hiroaki, et al.
Publicado: (2019)

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009)

Sequence-dependent attack on peptides by photoactivated platinum anticancer complexes
por: Wootton, Christopher A., et al.
Publicado: (2018)

Photoactivatable platinum anticancer complex can generate tryptophan radicals
por: Vallotto, Claudio, et al.
Publicado: (2018)

Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA
por: Morel, Elodie, et al.
Publicado: (2019)

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes
por: Shi, Huayun, et al.
Publicado: (2020)

Platinum–gold nanoraspberries as effective photosensitizer in anticancer photothermal therapy
por: Depciuch, J., et al.
Publicado: (2019)

DNA‐Intercalative Platinum Anticancer Complexes Photoactivated by Visible Light
por: Shi, Huayun, et al.
Publicado: (2021)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin
por: Barbanente, Alessandra, et al.
Publicado: (2021)

Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma
por: Utsumi, Fumi, et al.
Publicado: (2014)

Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review
por: Iwase, Akira, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4q7tgtpjsn3b2evhaum7iehslg